paclitaxel + carboplatin + farletuzumab

Combination regimen consisting of paclitaxel, carboplatin, and farletuzumab. **Paclitaxel** is a small molecule antineoplastic agent that stabilizes microtubules, inhibiting mitosis and tumor cell proliferation. **Carboplatin** is a platinum-based small molecule chemotherapeutic that induces DNA crosslinking, leading to apoptosis. **Farletuzumab** is a humanized monoclonal antibody targeting folate receptor alpha, highly expressed on epithelial ovarian cancer cells. Farletuzumab exerts anti-tumor effects via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity. The regimen has been studied in platinum-sensitive relapsed epithelial ovarian cancer to assess potential synergistic efficacy and safety, with trials suggesting activity and tolerability when compared to standard regimens[1][2][3][4].